We are live on ! Find out more
AEON icon

AEON Biopharma
AEON

21 hedge funds and large institutions have $20.5M invested in AEON Biopharma in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 13 reducing their positions, and 69 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.15% less ownership

Funds ownership: 1.24% → 0.1% (-1.1%)

75% less funds holding

Funds holding: 85 → 21 (-64)

85% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 13

92% less capital invested

Capital invested by funds: $248M → $20.5M (-$228M)

93% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 69

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
21
Holders Change
-64
Holders Change %
-75.29%
% of All Funds
0.33%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
5
Increased
2
Reduced
13
Closed
69
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SIM
Sandia Investment Management
Massachusetts
+$1.31M
2
Deutsche Bank
Deutsche Bank
Germany
+$546K
3
Walleye Capital
Walleye Capital
New York
+$161K
4
CCM
CAAS Capital Management
New York
+$119K
5
FTUS
Flow Traders U.S.
New York
+$107K

Top Sellers

Rank Fund Capital Flow
1
Marshall Wace
Marshall Wace
United Kingdom
-$13.3M
2
DKCM
Davidson Kempner Capital Management
New York
-$12.8M
3
AC
Aristeia Capital
Connecticut
-$12.6M
4
ECP
Empyrean Capital Partners
California
-$12.1M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$11.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
Janus Henderson Group
51
Janus Henderson Group
United Kingdom
– -$2.25M -3,113 Closed
Balyasny Asset Management
52
Balyasny Asset Management
Illinois
– -$2.25M -3,106 Closed
CSS
53
Cubist Systematic Strategies
Connecticut
– -$1.93M -2,669 Closed
Citadel Advisors
54
Citadel Advisors
Florida
– -$1.89M -2,617 Closed
DCM
55
Dupont Capital Management
Delaware
– -$1.51M -2,083 Closed
FCM
56
Farallon Capital Management
California
– -$1.51M -2,083 Closed
RCM
57
Rivernorth Capital Management
Florida
– -$1.41M -1,944 Closed
CL
58
CSS LLC
Illinois
– -$1M -1,389 Closed
MCM
59
Moore Capital Management
New York
– -$1.01M -1,389 Closed
AC
60
Athos Capital
Hong Kong
– -$898K -1,240 Closed
RL
61
RPO LLC
Connecticut
– -$861K -1,190 Closed
CC
62
Centiva Capital
New York
– -$839K -1,159 Closed
Ohio Public Employees Retirement System (OPERS)
63
Ohio Public Employees Retirement System (OPERS)
Ohio
– -$756K -1,045 Closed
PCM
64
Prelude Capital Management
New York
– -$652K -901 Closed
ASM
65
ATW SPAC Management
New York
– -$633K -875 Closed
Susquehanna International Group
66
Susquehanna International Group
Pennsylvania
– -$621K -859 Closed
EC
67
Elequin Capital
New York
– -$585K -808 Closed
COPPSERS
68
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
– -$503K -694 Closed
HF
69
HRT Financial
New York
– -$502K -694 Closed
SCM
70
Segantii Capital Management
Hong Kong
– -$503K -694 Closed
CCM
71
Context Capital Management
California
– -$498K -689 Closed
AR
72
Advisory Research
Illinois
– -$479K -662 Closed
SSA
73
Schonfeld Strategic Advisors
New York
– -$452K -625 Closed
Blackstone Inc
74
Blackstone Inc
New York
– -$403K -558 Closed
NAM
75
Nexpoint Asset Management
Texas
– -$400K -553 Closed
1 2
3
4

AEON Hedge Fund Activity: Q1 2023 in Review

21 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q1 2023, worth a combined $20.5M — down 92% from $248M a quarter earlier.

Sellers outnumbered buyers: 69 funds closed out of AEON and 5 opened new positions — a net loss of 64 holders — while 13 trimmed existing stakes and 2 added.

The largest buyer was Sandia Investment Management, opening a new position worth an estimated $1.31M. The largest seller was Marshall Wace, exiting entirely with an estimated $13.3M sold.

  • 21 institutional investors held AEON Biopharma (AEON) as of Q1 2023, down from 85 in Q4 2022.
  • Funds reported $20.5M of AEON Biopharma stock for Q1 2023, down 92% quarter-over-quarter.
  • 5 funds opened new AEON Biopharma positions in Q1 2023 and 69 closed out, a net change of -64 holders.
  • The largest AEON Biopharma buyer in Q1 2023 was Sandia Investment Management, an estimated $1.31M added.
  • The largest AEON Biopharma seller in Q1 2023 was Marshall Wace, an estimated $13.3M sold.

Based on aggregated 13F filings for Q1 2023.